Dapagliflozin is indicated for patients aged 18 years and over with T2DM for use as monotherapy to improve glycemic control in patients with inadequate glycemic control who are intolerant to metformin, and as an adjunct to diet and exercise in combination with other glucose-lowering medicinal agents in patients inadequately controlled on existing antidiabetic medications, including insulin [36]. This evidence concerns the gene INS and type 2 diabetes mellitus.